Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 28
Tirzepatide, CAVI, and arterial stiffness
A 2026 retrospective cohort found tirzepatide reduced CAVI from borderline to normal, alongside weight loss and glycaemic improvements, over 12.7 months.
Tirzepatide breast cancer: 2026 correction
A June 2026 Cureus correction updated an author affiliation in a tirzepatide and breast cancer narrative review. The scientific findings are unchanged.
Tirzepatide in type 1 diabetes: new data
A July 2026 cohort found 10% mean weight loss and lower insulin needs when tirzepatide was added to insulin in adults with type 1 diabetes.
Dapagliflozin plus semaglutide: BMI classes
A 328-patient Saudi cohort: proportional BMI response to dapagliflozin is uniform across obesity classes; semaglutide add-on helps most in class I.
GLP-1 drugs and micronutrient risk
How GLP-1 receptor agonists and dual incretin drugs create vitamin and mineral gaps, which nutrients are most at risk, and what monitoring looks like.
GLP-1 neuro research: what 20 years shows
A 2026 bibliometric analysis mapped 1,202 publications on GLP-1 receptor agonists in neurodegenerative disease from 2006 to 2025.
Incretins after bariatric surgery
A US cohort of 208,155 post-bariatric patients: tirzepatide beat semaglutide on weight loss (17.2% vs 12.0%). No significant cardiovascular signal either way.
Orforglipron for sleep apnea: ATTAIN-OSA
ATTAIN-OSA is testing an oral GLP-1 pill against sleep apnea. Here is what the 712-participant protocol measures and how it compares to SURMOUNT-OSA.
Semaglutide and OA: beyond weight loss
A 2026 preclinical study shows semaglutide reduces cartilage damage and joint pain without weight change, via GLP-1R activation of autophagy in chondrocytes.
Semaglutide in schizophrenia: HISTORI trial
Three randomised trials show semaglutide cuts weight and blood sugar in antipsychotic-treated patients without worsening psychiatric symptoms.
Masters athletes: supplement review 2026
A 2026 review in Current Sports Medicine Reports assessed protein, creatine, BPC-157, and TB-500 in adults over 55. Evidence is uneven.
Tesamorelin: what a cognition trial found
A 2026 pilot of low-dose tesamorelin found no significant changes on cognitive tests. Machine learning flagged shifts in two brain regions linked to attention.